Macrocycle goes full Circle
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
A triple-negative breast cancer face-off
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
The month ahead: September’s upcoming events
It’s back to school for biotech, with a packed conference schedule.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Corvus goes pivotal in peripheral T-cell lymphoma
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Opdualag sets its sights on lung
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
